By law, there is no way for other companies to make their own versions of biologicals, which are in a different category from standard drugs because they come from living cells. Health reform advocates want to change that. But the pharmaceutical industry is pushing back ferociously with a $66 million lobbying campaign to protect $46 billion in annual profits. It's a pivotal fight in the overall...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Price of biologic drugs often too high for poor
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account